Significant publications on infectious diseases pharmacotherapy in 2012

American Journal of Health-System Pharmacy

Volumn 70, Issue 21, 2013, Pages 1930-1940

  Bowers, Dana R ^a   Hunter, Andrew S ^b   Jacobs, David M ^a,c   Kuper, Kristi M ^d   Musick, William L ^e   Perez, Katherine K ^e   Shah, Dhara N ^a   Schilling, Amy N ^f  

^a UNIVERSITY OF HOUSTON   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Cardinal Health   (United States)

^d VHA Performance Services   (United States)

^e HOUSTON METHODIST HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; CEFEPIME; COLISTIN; LINEZOLID; VANCOMYCIN; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; BACTEREMIA; BLOODSTREAM INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENT; DIABETIC FOOT; DIABETIC FOOT INFECTION; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; MEDICAL SOCIETY; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC MYCOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84906845524     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130129     Document Type: Review

References (67)

1. Yeh RF, Kuper KM, Coyle EA et al. Significant publications on infectious diseases pharmacotherapy in 2007. Am J Health-Syst Pharm. 2008; 65:e72-9.
2. Kuper KM, Hirsch EB, Tam VH. Significant publications on infectious diseases pharmacotherapy in 2008. Am J Health-Syst Pharm. 2009; 66:1726-34.
3. Palmer HR, Cottreau JM, Garey KW et al. Significant publications on infectious diseases pharmacotherapy in 2009. Am J Health-Syst Pharm. 2010; 67:e34-42.
4. Hirsch EB, Cottreau JM, Ikwuagwu JO et al. Significant publications on infectious diseases pharmacotherapy in 2010. Am J Health-Syst Pharm. 2011; 68:2075-85.
5. Tran TT, Beyda ND, Biehle LR et al. Significant publications on infectious diseases pharmacotherapy in 2011. Am J Health-Syst Pharm. 2012; 69:1671-81.
6. Wunderink RG, Niederman MS, Kollef MH et al. Linezolid in methicillin-resistant Staphylococcus aureus pneumonia: a randomized controlled study. Clin Infect Dis. 2012; 54:621-9.
7. Van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012; 54:755-71.
8. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America; Pediatric Infectious Diseases Society. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol. 2012; 33:322-7.
9. Lipsky BA, Berendt AR, Cornia PB et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012; 54:e132-73.
10. Avdic E, Cushinotto LA, Hughes AH et al. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis. 2012; 54:1581-7.
11. Kullar R, Davis SL, Taylor TN et al. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy. 2012; 32:195-201.
12. Chopra T, Marchaim D, Veltman J et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother. 2012; 56:3936-42.
13. Dalfino L, Puntillo F, Mosca A et al. Highdose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012; 54:1720-6.
14. Park WB, Kim NH, Kim KH et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012; 55:1080-7.
15. Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012; 56:2108-13.
16. Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012; 12:281-9.
17. Ray WA, Murray KT, Hall K et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366:1881-90.
18. Rodriguez-Bano J, Navarro MD, Retamar P et al. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamaseproducing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012; 54:167-74.
19. Felton TW, Hope WW, Lomaestro BM et al. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. Antimicrob Agents Chemother. 2012; 56:4087-94.
20. McGowan JE. Antimicrobial stewardship - the state of the art in 2011: focus on outcome and methods. Infect Control Hosp Epidemiol. 2012; 33:331-7.
21. Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012; 55:943-50.
22. Wieland BW, Marcantoni JR, Bommarito KM et al. A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillinsusceptible Staphylococcus aureus. Clin Infect Dis. 2012; 54:585-90.
23. Kollef MH, Chastre J, Clavel M et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care. 2012; 16:R218.
24. Crook DW, Walker AS, Kean Y et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012; 55(suppl 2):S93-103.
25. Kang DH, Kim YJ, Kim SH et al. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med. 2012; 366:2466-73.
26. Sandberg T, Skoog G, Hermansson AB et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012; 380:484-90.
27. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis. 2012; 54:96-104.
28. Ho TT, Cadena J, Childs LM et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012; 67:1267-70.
29. Sakoulas G, Bayer AS, Pogliano J et al. Ampicillin enhances daptomycin and cationic host defense peptide-mediated killing of ampicillin- and vancomycinresistant Enterococcus faecium. Antimicrob Agents Chemother. 2012; 56:838-44.
30. Dolton MJ, Ray JE, Chen SC et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother. 2012; 56: 4793-9.
31. Chow AW, Benninger MS, Brook I et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012; 54:1041-5.
32. Le F, Arora V, Shah DN et al. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy. 2012; 32:129-34.
33. Klein NP, Bartlett J, Rowhani-Rahbar A et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012; 367:1012-9.
34. Shulman ST, Bisno AL, Clegg HW et al. Clinical practice guidelines for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012; 55:1279-82.
35. Baeten JM, Donnell D, Ndase P et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367:399-410.
36. DeJesus E, Rockstroh JK, Henry K et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, noninferiority trial. Lancet. 2012; 379:2429-38.
37. Sax PE, DeJesus E, Mills A et al. Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012; 379:2439-48.
38. Thigpen MC, Kebaabetswe PM, Paxton LA et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367:423-34.
39. Nielsen-Saines K, Watts DH, Veloso VG et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012; 366:2368-79.
40. Van Lunzen J, Maggiolo F, Arribas JR et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviralnaive adults with HIV: planned interim 48 week results from SPRING-1, a doseranging, randomised, phase 2b trial. Lancet Infect Dis. 2012; 12:111-8.
41. Violari A, Lindsey JC, Hughes MD et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med. 2012; 366:2380-9.
42. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/America Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44(suppl 2):S27-72.
43. Krakower D, Mayer KH. What primary care providers need to know about preexposure prophylaxis for HIV prevention. Ann Intern Med. 2012; 157:490-7.
44. Falagas ME, Karageorgopoulos DE. Extended-spectrum β-lactamase-producing organisms. J Hosp Infect. 2009; 73:345-54.
45. Kang CI, WI YM, Lee MY et al. Epidemiology and risk factors of community onset infectious caused by extended-spectrum β-lactamase-producing Escherichia coli strains. J Clin Microbiol. 2012; 50:312-7.
46. Rodríguez-Baño J, Picón E, Gijón P et al. Community-onset bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010; 50:40.
47. Lee CC, Lee NY, Yan JJ et al. Bacteremia due to extended-spectrum β-lactamase producing Enterobacter cloacae: the role of carbapenem therapy. Antimicrob Agents Chemother. 2010; 54:3551-6.
48. Paterson DL, Ko WC, von Gottberg A et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extendedspectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001; 39:2206-12.
49. Kim YK, Pai H, Lee HJ et al. Bloodstream infections by extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother. 2002; 46:1481-91.
50. Clinical and Laboratory Standards Institute. CLSI document M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
51. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health- System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009; 66:82-98.
52. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011; 52:e18-55.
53. Lipsky BA, Berendt AR, Deery HG et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004; 39:885-910.
54. Eleftheriadou I, Tentolouris N, Argiana V et al. Methicillin-resistant Staphylococcus aureus in diabetic foot infection. Drugs. 2010; 70:1785-97.
55. Levin MD, den Hollander JG, van der Holt B et al. Hepatoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. Antimicrob Agents Chemother. 2007; 60:1104-7.
56. Trifilio SM, Yarnold PR, Scheetz MH et al. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother. 2009; 53:1793-6.
57. Pascual A, Calandra T, Bolay S et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008; 46:201-11.
58. Troke PF, Hockey HP, Hope WW et al. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother. 2011; 55:4782-8.
59. Shimizu T, Ochiai H, Asell F et al. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2c19. Drug Metab Pharmacokinet. 2003; 18:48-70.
60. Gupta N, Limbago LM, Patel JB et al. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011; 53:60-7.
61. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44:159-77.
62. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother. 1998; 42:1303-4.
63. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycinintermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007; 60:788-94.
64. Kalil AC, Murthy MH, Hermsen ED et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med. 2010; 38:1802-8.
65. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs. glycopeptide antibiotics for the treatment of suspected methicillinresistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest. 2011; 139:1148-55.
66. Chan JD, Pham TN, Wong J et al. Clinical outcomes of linezolid vs. vancomycin in methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia: retrospective analysis. J Intensive Care Med. 2011; 26:385-91.
67. Torres A. Antibiotic treatment against methicillin-resistant Staphylococcus aureus hospital and ventilator acquired pneumonia: a step forward but the battle continues. Clin Infect Dis. 2012:54:630-2.